Phase I/II Study of FP-045 in Patients With Fanconi Anemia
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Phase 1 dose escalation in adolescents (ages 12-18 y.o.). Once safety established, dose
escalation in pediatric subjects (3-11 y.o.) will follow. In expansion phase 20 adolescent or
pediatric subjects will receive FP-045 at recommended phase 2 dose for 6 months.